Zydus Lifesciences is currently trading at Rs. 1177.05, up by 28.20 points or 2.45% from its previous closing of Rs. 1148.85 on the BSE.
The scrip opened at Rs. 1213.95 and has touched a high and low of Rs. 1213.95 and Rs. 1148.00 respectively. So far 35936 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1213.95 on 24-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023.
Last one week high and low of the scrip stood at Rs. 1213.95 and Rs. 1122.00 respectively. The current market cap of the company is Rs. 118750.70 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.22% and 6.79% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg (USRLD: Diovan tablets). Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and paediatric patients one year of age and older. It is also used in adults to treat heart failure (a condition in which the heart is unable to pump enough blood to the rest of the body) and to improve survival after a heart attack.
The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India. Valsartan tablets had annual sales of $149.5 million in the United States (IQVIA MAT May 2024). The group now has 400 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |